Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GARDASIL 9 Safety and Immunogenicity in Vietnam
NCT03546842Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2018
- Primary completion
- Jan 2019
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of recombinant human papillomavirus 9-valent vaccine in human papillomavirus infection, sponsored by Merck & Co. Primary endpoint: Seroconversion Percentages to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 7. Started Jun 2018; status: completed.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT03546842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03546842.